PRPO — Precipio, Inc.

Summary of Precipio (PRPO) Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $24 million for FY 2025, a 30% increase year-over-year.
• Gross Margin: Improved from 41% in 2024 to 45% in 2025, with a notable spike to 90% in Q4 due to strategic inventory production.
• Pathology Services Division: Continued strong organic growth, serving as the financial backbone of the company.
• Products Division: Margins temporarily affected by investments, but expected to improve as sales team expands and customer onboarding progresses.

2. Strategic Updates and Business Highlights:

• Transitioned from a cash-using to a self-sustaining business with positive cash flow.
• Completed repayment of the Change Healthcare loan, leading to a cleaner balance sheet.
• Strengthened the commercial team by hiring a Chief Commercial Officer and two business development officers to drive growth in the Products division.
• Enhanced operational efficiencies and customer onboarding processes, with a focus on expanding the HemeScreen and Bloodhound product lines.

3. Forward Guidance and Outlook:

• Plans to accelerate the adoption of HemeScreen and Bloodhound products in 2026, targeting a more balanced revenue mix between pathology services and products.
• Anticipates continued growth in the Pathology Services division, which will support reinvestment into the Products division.
• Identified significant market opportunities in acute myeloid leukemia (AML) testing, with plans to launch a rapid testing service.

4. Bad News, Challenges, or Points of Concern:

• Products division revenues did not grow as expected due to operational fluctuations from existing customers and a limited commercial team.
• Temporary loss of revenues from customer pauses due to internal issues, which were addressed with new business continuity measures.
• The need for improved customer onboarding processes and the potential for delays in revenue recognition from new laboratory customers.

5. Notable Q&A Insights:

• Management acknowledged the challenges faced in the Products division but expressed confidence in the newly expanded sales team and improved operational strategies.
• Emphasized the importance of maintaining strong relationships with distributors to enhance market reach.
• Discussed the company's commitment to engaging with investors more actively, contributing to a 300% share price appreciation in 2025.

Overall, Precipio demonstrated significant progress in 2025, achieving financial milestones and laying the groundwork for future growth, despite facing challenges in the Products division. The focus for 2026 will be on executing growth strategies and enhancing market share.